Nan Fung Trinity HK Ltd. Buys 68,360 Shares of Xenon Pharmaceuticals Inc. $XENE

Nan Fung Trinity HK Ltd. raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 43.1% in the 4th quarter, Holdings Channel reports. The firm owned 226,965 shares of the biopharmaceutical company’s stock after purchasing an additional 68,360 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Xenon Pharmaceuticals were worth $10,173,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Danske Bank A S bought a new position in Xenon Pharmaceuticals during the 3rd quarter worth $32,000. Blue Trust Inc. raised its position in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals in the 3rd quarter worth about $39,000. Osaic Holdings Inc. raised its position in shares of Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares in the last quarter. Finally, State of Wyoming raised its position in shares of Xenon Pharmaceuticals by 112.8% in the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on XENE shares. Robert W. Baird lifted their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Royal Bank Of Canada lifted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Wells Fargo & Company lifted their price objective on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $74.50.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $56.44 on Friday. The stock has a 50-day moving average of $54.64 and a 200-day moving average of $46.62. The company has a market cap of $5.45 billion, a PE ratio of -12.01 and a beta of 0.65. Xenon Pharmaceuticals Inc. has a one year low of $28.19 and a one year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting the consensus estimate of ($1.17). During the same period last year, the company earned ($0.83) earnings per share. Analysts expect that Xenon Pharmaceuticals Inc. will post -4.83 EPS for the current fiscal year.

Insider Activity

In other news, insider Andrea Difabio sold 1,342 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider directly owned 7,301 shares in the company, valued at $403,234.23. This trade represents a 15.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $403,620.84. Following the transaction, the chief executive officer owned 19,923 shares of the company’s stock, valued at $1,100,347.29. This trade represents a 26.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 296,707 shares of company stock worth $17,845,365 in the last three months. Company insiders own 4.07% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Xenon Pharmaceuticals from $80 to $82 and reaffirmed an outperform rating, signaling confidence in further upside. RBC price target update
• Positive Sentiment: Xenon reported Q1 2026 earnings of -$1.17 per share, matching analyst expectations and reducing uncertainty around the quarter. The company also said it provided a business update alongside the results. Q1 2026 financial results and business update
• Neutral Sentiment: Needham & Company lowered its price target slightly from $80 to $78 but kept a buy rating, which still points to substantial upside from current levels. Needham price target update
• Neutral Sentiment: The company’s earnings call transcript and earnings snapshot are drawing investor attention, but no additional major surprise was highlighted in the available items. Q1 2026 earnings call transcript

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.